Sipuleucel-T in prostate cancer: Added benefit is not proven

8 enero 2015

Evaluators report that data on survival were not evaluable because group differences might have been caused by the circumstances of the subsequent therapies when reviewing the potential added benefit of Sipulecuel-T. Certain side effects such as fever were found to be more frequent.